New 3-aminorhodanine derivatives: Synthesis, characterization, docking study and biological activates
Open Access
- 18 October 2023
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 12, 1365
Abstract
Background: Epidermal growth factor receptor (EGFR) is seen in almost all cases of non-small cell lung cancer (NSCLC). As a result, targeting EGFR has become an attractive subject of research in fields such as antitumor research and the most important strategy for cancer treatment, in particular, in the treatment of non-small-cell lung malignancies using EGFR-targeting therapies. Methods: For this purpose, novel N- and 5- disubstituted aminorhodanine derivatives were synthesized by Schiff base and using a Knoevenagel condensation approach over two steps of reactions. Then, rhodanine derivatives were analyzed their cytotoxic effect on A549 lung cancer and Hdfn normal cell and compared the analysis result with erlotinib (anticancer drug) as standard to determine their activities on cancer cell and toxicity or safety on normal cell. Results: Synthetic compounds (2a1-2, 2b1-2) showed different effects at 24, 48 and 72h. The higher anticancer effect was seen for 2a2 and 2a1with IC50 10 μg/mL and 32.59 μg/mL, respectively, at 24h and 72 h. Also, they show high anticancer potency at 72h with low effect and high safety on human normal cell. Conclusions: Developing a new series of rhodanine derivatives and evaluating their anticancer activity is the main goal of the study. In silico and in vitro antitumor investigations for newly synthesized compounds with different properties and functional group in chemical structure revealed different activities against lung cancer cell. Compounds 2a1-2 which contain pyridine ring in their chemical structure showed more potent effect than the derivative that bearing furyl ring (2b1-2).Keywords
This publication has 52 references indexed in Scilit:
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase InhibitorsMolecules, 2010
- Five‐year lung cancer survivalCancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvationJournal of Molecular Biology, 1995